Diffuse low-grade glioma form a rare entity affecting young people. Despite advances in surgery, chemotherapy, and radiation therapy, diffuse low-grade glioma are still incurable. According to current guidelines, maximum safe resection, when feasible, is the first line of treatment. Apart from surgery, all other treatment modalities (temozolomide, procarbazine-CCNU-vincristine regimen, and radiation therapy) are handled very differently among different teams, and this in spite of recent results of several phase 3 studies. Based on a European survey, this paper aimed to get a picture of this heterogeneity in diffuse low-grade glioma management, to identify clinically relevant questions raised by this heterogeneity of practice, and to propose new methodological frameworks to address these questions.
Survey on current practice within the European Low-Grade Glioma Network: where do we stand and what is the next step? / Mandonnet, Emmanuel; Wager, Michel; Almairac, Fabien; Baron, Marie-Helene; Blonski, Marie; Freyschlag, Christian F; Barone, Fabio; Fontaine, Denys; Pallud, Johan; Hegi, Monika; Viegas, Catarina; Zetterling, Maria; Spena, Giannantonio; Goodden, John; Rutten, Geert-Jan; Taillandier, Luc; Foroglu, Nicolas; Darlix, Amélie; Skrap, Miran; Martino, Juan; von Campe, Gord; Madadaki, Caterina; Gayat, Etienne; de Witt Hamer, Philip; Gil Robles, Santiago; Sarubbo, Silvio; Santarius, Thomas; Bello, Lorenzo; Forster, Marie-Therese; Duffau, Hugues. - In: NEURO ONCOLOGY PRACTICE. - ISSN 2054-2585. - 4:4(2017), pp. 241-247. [10.1093/nop/npw031]
Survey on current practice within the European Low-Grade Glioma Network: where do we stand and what is the next step?
Sarubbo, Silvio;
2017-01-01
Abstract
Diffuse low-grade glioma form a rare entity affecting young people. Despite advances in surgery, chemotherapy, and radiation therapy, diffuse low-grade glioma are still incurable. According to current guidelines, maximum safe resection, when feasible, is the first line of treatment. Apart from surgery, all other treatment modalities (temozolomide, procarbazine-CCNU-vincristine regimen, and radiation therapy) are handled very differently among different teams, and this in spite of recent results of several phase 3 studies. Based on a European survey, this paper aimed to get a picture of this heterogeneity in diffuse low-grade glioma management, to identify clinically relevant questions raised by this heterogeneity of practice, and to propose new methodological frameworks to address these questions.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
